Guided Therapeutics Reported Earnings

Guided Therapeutics (GTHP) reported a loss of $0.01 per share on revenue of $0.00 million for the . . Revenue fell 100.00% compared to the same quarter a year ago.

GUIDED THERAPEUTICS, Inc. is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are available immediately. GT also owns technology for measuring substances in interstitial fluid, a secondary circulatory system in the body that surrounds the cells.